IRIS
MARTINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 50.033
AS - Asia 4.684
NA - Nord America 2.474
SA - Sud America 333
AF - Africa 82
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 57.616
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 49.181
US - Stati Uniti d'America 2.320
SG - Singapore 2.146
CN - Cina 1.171
VN - Vietnam 723
FR - Francia 431
BR - Brasile 207
BD - Bangladesh 194
HK - Hong Kong 152
FI - Finlandia 92
DE - Germania 82
CH - Svizzera 77
MX - Messico 58
GB - Regno Unito 52
AR - Argentina 50
CA - Canada 48
JP - Giappone 48
IN - India 40
IQ - Iraq 29
ZA - Sudafrica 29
NL - Olanda 22
EC - Ecuador 21
ID - Indonesia 20
RU - Federazione Russa 19
PH - Filippine 18
TR - Turchia 15
TH - Thailandia 14
CO - Colombia 13
JM - Giamaica 13
PK - Pakistan 13
VE - Venezuela 13
CL - Cile 12
DZ - Algeria 12
KR - Corea 12
IE - Irlanda 11
JO - Giordania 11
CR - Costa Rica 10
KE - Kenya 9
MA - Marocco 9
PY - Paraguay 9
TW - Taiwan 9
NP - Nepal 8
SE - Svezia 8
AT - Austria 7
PL - Polonia 7
SA - Arabia Saudita 7
UA - Ucraina 7
EG - Egitto 6
ES - Italia 6
KZ - Kazakistan 6
RO - Romania 6
AU - Australia 5
BY - Bielorussia 5
GT - Guatemala 5
MY - Malesia 5
AZ - Azerbaigian 4
LT - Lituania 4
OM - Oman 4
PE - Perù 4
PR - Porto Rico 4
QA - Qatar 4
SY - Repubblica araba siriana 4
UZ - Uzbekistan 4
HN - Honduras 3
HR - Croazia 3
IL - Israele 3
LB - Libano 3
MM - Myanmar 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GM - Gambi 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
TN - Tunisia 2
AD - Andorra 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CD - Congo 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
ET - Etiopia 1
IR - Iran 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
Totale 57.598
Salva come PNG Salva come JPEG
Città #
Genova 32.785
Genoa 9.439
Rapallo 4.079
Vado Ligure 2.570
Singapore 1.033
San Jose 789
Ashburn 458
Lauterbourg 412
Ho Chi Minh City 204
Beijing 186
Hanoi 166
New York 165
Hong Kong 144
Helsinki 88
Santa Clara 85
Zurich 72
Bordighera 65
Frankfurt am Main 61
Council Bluffs 58
Los Angeles 46
Tokyo 44
Haiphong 38
Mexico City 34
Da Nang 28
Milan 24
Tianjin 22
Rome 21
Amsterdam 19
Orem 18
Phoenix 18
Buffalo 17
Chicago 17
Naples 16
Atlanta 15
City of London 15
Dallas 14
Baghdad 13
Nuremberg 13
São Paulo 13
Cardiff 12
Guangzhou 11
Johannesburg 11
Denver 10
Dublin 10
Hải Dương 10
Pasadena 10
Amman 9
Chennai 9
Montreal 9
Toronto 9
Biên Hòa 8
Guayaquil 8
Phủ Lý 8
Thái Nguyên 8
Houston 7
Kingston 7
Quito 7
Rio de Janeiro 7
San José 7
Shanghai 7
Ankara 6
Bangkok 6
Bari 6
Boardman 6
Can Tho 6
Cape Town 6
Charlotte 6
Des Moines 6
Long Xuyen 6
Nairobi 6
New Delhi 6
San Francisco 6
Santiago 6
Seattle 6
Shenzhen 6
Berlin 5
Caxias do Sul 5
Hưng Yên 5
Jakarta 5
London 5
Miami 5
Ninh Bình 5
Paris 5
Poplar 5
Porto Alegre 5
Rudolfstetten 5
Warsaw 5
Almaty 4
Baku 4
Bologna 4
Brooklyn 4
Changsha 4
Delhi 4
Doha 4
Florence 4
Guatemala City 4
Lahore 4
Muscat 4
New Taipei City 4
Riyadh 4
Totale 53.690
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 271
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 260
CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever 243
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 235
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 232
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 212
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 212
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 208
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 206
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 206
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 203
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 201
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 200
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 200
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 198
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 198
Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: Clinical and therapeutic implications 197
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 197
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 194
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 194
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 193

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 192
HLA-DRB1∗11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis 191
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 190
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. 185
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 185
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 185
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 184
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 184
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 184
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 184
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 183
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 182
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 182
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 181
Differentiating PFAPA syndrome from monogenic periodic fevers. 181
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 180
A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment 179
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 178
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 175
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 175
Advances in biomarkers for paediatric rheumatic diseases 174
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features 173
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 173
The role of imaging in juvenile idiopathic arthritis 172
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 172
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 171
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 169
Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases 169
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 169
Cryopyrin-associated periodic syndromes in Italian Patients: Evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization 169
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. 168
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 168
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 166
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 166
The EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: ankara 2008. part ii: final classification criteria. 165
Preliminary definition of improvement in juvenile arthritis. 165
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 164
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 163
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 163
Antiphospholipid antibody syndrome in pediatric patients. 163
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 163
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 162
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 162
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 162
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice 162
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 162
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 162
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 161
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 161
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 161
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 160
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 160
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 160
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 158
Criteria to define response to therapy in paediatric rheumatic diseases. 158
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 158
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children 158
Paediatric-onset systemic lupus erythematosus. 158
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients 158
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 158
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 157
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 157
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. 157
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 156
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians 156
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 156
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis 156
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 156
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. 155
A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis 154
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 154
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 153
In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist 153
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 153
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients 153
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 153
Chronic recurrent multifocal osteomyelitis with unusual features. 152
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. 152
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 152
Totale 17.621
Salva come PNG Salva come JPEG
Categoria #
all - tutte 183.881
article - articoli 181.570
book - libri 0
conference - conferenze 314
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.997
Totale 367.762
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021285 0 0 0 0 0 0 0 0 0 0 0 285
2021/20225.612 171 427 630 448 325 240 441 1.288 206 453 330 653
2022/20234.949 550 245 44 420 847 977 23 467 920 33 345 78
2023/20242.129 147 374 45 210 197 346 117 134 96 53 105 305
2024/20256.173 98 574 247 384 818 675 545 875 310 360 501 786
2025/202611.585 1.203 404 625 925 1.536 1.363 2.031 557 855 1.179 692 215
Totale 58.187